araag2/HINT huggingface dataset:
Clinical trial NCT02213133 (phase 2, status: terminated)
Conditions: squamous cell carcinoma
ICD codes: C44.520, C44.92, C44.02, C44.321, C44.521, C44.82, C44.42
Drugs: selinexor (kpt-330)
SMILES: FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F
Reason stopped: 
    due to enrollment challenges and availability of other options for lung cancer patients. the
    termination is not a consequence of any safety concern.
  
Eligibility criteria:

        Inclusion Criteria:

          -  18 years of age or older

          -  confirmed SCC of the head and neck, lung, or esophagus

          -  1 to 2 prior therapies

          -  measurable disease at screening and documented progression within the past 6 weeks

        Exclusion Criteria:

          -  patients requiring total parenteral nutrition

          -  unstable cardiovascular function

          -  substantially impaired gastrointestinal function

          -  Symptomatic brain metastases

          -  another malignancy within 3 years except adequately treated in situ carcinoma of any
             type, basal or non-melanomatous skin cancer
Clinical trial NCT02213744 (phase 2/phase 3, status: terminated)
Conditions: breast cancer, her2 positive breast cancer
ICD codes: C79.81, D24.1, D24.2, D24.9, D49.3, C44.501, D48.60
Drugs: mm-302, gemcitabine, capecitabine, vinorelbine, trastuzumab
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][C@@]12N(C)C3=CC(OC)=C(C=C3[C@@]11CCN3CC=C[C@](CC)([C@@]13[H])[C@@]([H])(OC(C)=O)[C@]2(O)C(=O)OC)[C@]1(C[C@@]2([H])CN(CC(CC)=C2)CC2=C1NC1=CC=CC=C21)C(=O)OC, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    felt not to show benefit over control per dmc and confirmed via futility analysis
  
Eligibility criteria:

        Inclusion Criteria:

          -  Patients must have histologically or cytologically confirmed invasive cancer of the
             breast

          -  Patients must have documented locally advanced/metastatic disease, defined by the
             investigator, which is not amenable to resection with curative intent.

          -  Patients must have HER2-positive breast cancer as defined by ASCO/CAP 2013 guidelines
             that is confirmed by a Sponsor-designated central laboratory

          -  Patients must have progressed on, or be intolerant to pertuzumab in the LABC/MBC
             setting or had disease recurrence within 12 months of pertuzumab treatment in the
             neoadjuvant or adjuvant setting.

          -  Patients must have progressed on, or be intolerant to ado-trastuzumab emtansine in the
             LABC/MBC setting

          -  Patients must have been previously treated with trastuzumab in any setting (which may
             have been previously administered with or without pertuzumab)

          -  ECOG Performance Status of 0 or 1

        Exclusion Criteria:

          -  Patients who have previously been treated with doxorubicin, liposomal doxorubicin,
             epirubicin, mitoxantrone, or any other anthracycline derivative

          -  Subjects with central nervous system (CNS) metastases, unless they have been treated
             and are stable without symptoms for 4 weeks after completion of treatment and must be
             off steroids for at least 4 weeks prior to enrollment

          -  Patients with any class of New York Heart Association (NYHA) CHF or heart failure with
             preserved ejection fraction (HFPEF)

          -  Patients with a history of known coronary artery disease or a myocardial infarction
             within the last 12 months

          -  Patients with a known history of serious cardiac arrhythmias requiring treatment
             (exception: controlled atrial fibrillation, paroxysmal supraventricular tachycardia)

          -  Patients who previously discontinued trastuzumab due to unacceptable cardiac toxicity

          -  Patients with a history of LVEF decline to below 50% during or after prior
             trastuzumab/lapatinib or other HER2 directed therapy.
Clinical trial NCT02216097 (phase 2, status: terminated)
Conditions: post-traumatic stress disorder
ICD codes: F43.10, F43.11, F43.12
Drugs: pf-04457845, placebo
SMILES: FC(F)(F)C1=CC=C(OC2=CC=CC(C=C3CCN(CC3)C(=O)NC3=CC=CN=N3)=C2)N=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    the study stopped based on pfizer portfolio prioritization and not due to safety and/or
    efficacy concern or change in benefit:risk assessment of pf-04457845.
  
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women 18-60 years of age with a primary psychiatric diagnosis of Post
             Traumatic Stress Disorder

        Exclusion Criteria:

          -  Other psychiatric illness requiring current treatment with medication.
Clinical trial NCT02216149 (phase 2, status: terminated)
Conditions: esophagus cancer, stomach cancer, small bowel cancer, colon cancer, rectum cancer
ICD codes: D13.0, C15.9, C15.3, C15.4, C15.5, C15.8, Z85.01, D13.1, C16.9, C16.1, C16.2, D37.1, C16.8, C16.5, C05.2, C10.0, C16.0, C16.4, C17.0, C17.1, C17.2, C18.2, C18.4, C18.6, C18.7, C18.9, D12.2, D12.3, C20, D12.8, D37.5, C78.5, Z12.12, C21.8, Z85.048
Drugs: s-1, capecitabine, oxaliplatin
SMILES: [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1, [H][N]1([H])[C@@H]2CCCC[C@H]2[N]([H])([H])[Pt]11OC(=O)C(=O)O1
Reason stopped: 
    slow accrual
  
Eligibility criteria:

        Inclusion Criteria:

          -  Has given written informed consent.

          -  Is at least 18 years of age.

          -  Has advanced or metastatic gastrointestinal tract adenocarcinoma.

          -  No previous cancer chemotherapy for cancer.

          -  Measurable or evaluable lesions according to RECIST v1.1 criteria.

          -  Is able to take medications orally.

          -  Has ECOG performance status 0 or 1.

          -  Has a life expectancy of at least 3 months.

          -  Has adequate organ function.

        Exclusion Criteria:

          -  Cancer considered operable without prior chemotherapy.

          -  Prior chemotherapy to cancer.

          -  Previous therapy with fluoropyrimidines or anthracyclines for any indication.

          -  Inability to swallow tablets.

          -  Known brain metastasis or leptomeningeal metastasis.

          -  History of myocardial infarction, coronary stenting/graft.

          -  History of unstable angina, coronary/peripheral artery bypass graft.

          -  History of cerebrovascular accident or transient ischemic attack.

          -  History of pulmonary embolism or deep vein thrombosis.

          -  Symptomatic congestive heart failure.

          -  Ongoing cardiac dysrhythmias.

          -  Patients with any cardiac disease that requires regular medication.

          -  Hypertensive crisis or severe hypertension that is not controlled.

          -  Is a pregnant or lactating female.

          -  The cardiac arterial flow tests cannot be done.
Clinical trial NCT02219048 (phase 2, status: terminated)
Conditions: asthma
ICD codes: J45.998, J82.83, J45.909, J45.991, J45.20, J45.30, J45.40
Drugs: placebo, pf-03715455
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O, CC(C)(C)C1=NN(C(NC(O)=NCC2=CC=CC=C2SC2=CN3C(C=C2)=NN=C3C2=CC=CC=C2SCCO)=C1)C1=CC(Cl)=C(O)C=C1
Reason stopped: 
    the termination was due to business reasons. no safety or efficacy concerns contributed to the
    termination of the study
  
Eligibility criteria:

        Inclusion Criteria:

          -  Subjects with a physician documented history or diagnosis of persistent asthma
             (according to GINA, 2014 definition of asthma),

          -  Pre bronchodilator FEV1 of greater than or equal to 50 and less that 80% of predicted.

          -  Subjects defined as GINA Step 4 on a stable dose of either fluticasone/salmeterol
             combination therapy, or budesonide/formoterol combination therapy or
             mometasone/formoterol combination therapy.

          -  Subjects who are defined as uncontrolled as evidenced by; Juniper Asthma Control
             Questionnaire (5 item version, ACQ) score greater than or equal to 1.5 and less than
             or equal to 3.0)

        Exclusion Criteria:

          -  Subjects diagnosed with chronic pulmonary disease (COPD) and/or other chronic
             pulmonary diseases (eg, Occupational asthma, pulmonary fibrosis, bronchiectasis,
             Allergic bronchopulmonary aspergillosis (ABPA), pneumoconiosis, sarcoidosis,
             tuberculosis).

          -  Subjects who are current smokers.
Clinical trial NCT02219685 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof, placebo
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Chronic HCV infection (≥ 6 months) documented by prior medical history or liver biopsy

          -  Chronic genotype 1 HCV infection

          -  Screening laboratory values within defined thresholds

          -  Use of protocol-specified method(s) of contraception if female of childbearing
             potential or sexually active male

        Exclusion Criteria:

          -  Clinically-significant illness (other than HCV) or any other major medical disorder
             that may interfere with treatment, assessment, or compliance with the protocol.
             Current or prior history of any of the following:

               -  Hepatic decompensation

               -  Solid organ transplantation

               -  Significant pulmonary or cardiac disease

               -  Chronic liver disease of a non-HCV etiology

               -  Hepatocellular carcinoma (HCC)

               -  Infection with hepatitis B virus (HBV)

               -  Infection with human immunodeficiency virus (HIV)

               -  History of recent epilepsy (within 2 years of screening) or cerebral vascular
                  accident (CVA)

               -  Structural brain damage

          -  Presence of cirrhosis

          -  Contraindication to MRI

          -  Pregnant or nursing female

          -  Prior treatment NS5A directly-acting antiviral agent. Any interferon (IFN)-containing
             regimen within 8 weeks of Screening
Clinical trial NCT02222350 (phase 2, status: completed)
Conditions: type 2 diabetes mellitus
ICD codes: E11.65, E11.9, E11.21, E11.36, E11.41, E11.42, E11.44
Drugs: 10mg ds-8500a tablet, 75mg ds-8500a tablet, placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Patients aged ≥ 20 years at the time of informed consent

          -  Japanese patients with type 2 diabetes

          -  Patients who have HbA1c ≥ 7.0% and < 10.0% if untreated with antidiabetic agent.

          -  Patients who have HbA1c ≥ 6.5% and < 9.5% if treated with antidiabetic agent.

        Exclusion Criteria:

          -  Patients aged ≥ 70 years at the time of informed consent

          -  Patients with a history of type 1 diabetes or diabetic ketoacidosis

          -  Patients receiving or requiring treatment with insulin

          -  Patients with a body mass index (BMI) of < 18.5 kg/m2 or ≥ 35.0 kg/m2

          -  Patients with an estimated glomerular filtration rate (eGFR), < 45 mL/min per 1.73 m2

          -  Patients with fasting plasma glucose ≥ 240 mg/dL
Clinical trial NCT02222714 (phase 2, status: completed)
Conditions: ischemic stroke
ICD codes: I25.5, H47.013, H93.013, G45.9, H47.011, H47.012, H47.019
Drugs: placebo
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Eligibility criteria:

        Inclusion Criteria:

          -  Acute ischemic stroke

          -  Able to receive IV tPA, mechanical thrombectomy or both

          -  National Institutes of Health Stroke Scale (NIHSS) score of ≥ 5

          -  Signed informed consent

          -  Mechanical thrombectomy subjects only: onset time to arterial puncture time < 6 hours

        Exclusion Criteria:

          -  History of stroke or penetrating head injury within 90 days prior to enrollment

          -  History of previous or current diagnosis of intracranial hemorrhage that represents a
             potential for re-hemorrhage if subjected to thrombolytic therapy or mechanical
             thrombectomy

          -  Moyamoya disease, cerebral arterio-venous malformation (AVM), known unsecured aneurysm
             requiring intervention during the acute study period

          -  Presence of other neurological or non-neurological co-morbidities that may lead,
             independently of the current stroke, to further deterioration in the subject's
             neurological status during the trial period

          -  Presence of premorbid neurological deficits and functional limitations assessed by a
             retrospective Modified Rankin Scale (mRS) score of ≥ 2

          -  Mechanical thrombectomy subjects only: baseline non-contrast CT scan revealing a large
             core occlusion as defined by local protocol

          -  Prolonged prothrombin time (PT) or activated partial thromboplastin time (aPTT)

          -  Severe hypertension or hypotension

          -  Glomerular filtration rate (GFR) <35 mL/min

          -  Blood glucose concentration < 50 mg/dL

          -  Prior exposure to any exogenous form of APC
Clinical trial NCT02222948 (phase 2, status: terminated)
Conditions: relapsing-remitting multiple sclerosis
ICD codes: G35, G93.81, K74.1, Q85.1, G12.21, G12.23, M34.0
Drugs: vatelizumab, placebo (for vatelizumab)
SMILES: CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    study discontinued based on planned interim analysis of the primary endpoint. not linked to any
    safety concern.
  
Eligibility criteria:

        Inclusion criteria:

        Diagnosis of relapsing-remitting multiple sclerosis (RRMS). At least 1 documented relapse
        in the past 12 months. At least 1 contrast-enhancing lesion (CEL) on magnetic resonance
        imaging (MRI) in the past 12 months and/or at screening.

        At least 3 T2 lesions on screening MRI.

        Exclusion criteria:

        Diagnosis of primary progressive or secondary progressive MS. Expanded disability status
        scale (EDSS) score >5.5. Relapse within 30 days prior to enrollment. Prior
        immunosuppressive treatment within protocol-specified time periods. Prior treatment with
        natalizumab (Tysabri®). History of bleeding/platelet disorders, malignancy, certain
        infections as defined in the protocol, or any other past or current medical conditions that
        would adversely affect the patient's participation in the study.

        Pregnancy or breast-feeding. Other protocol-defined inclusion/exclusion criteria may apply.

        The above information is not intended to contain all considerations relevant to a patient's
        potential participation in a clinical trial.
Clinical trial NCT02223260 (phase 2, status: completed)
Conditions: venous thromboembolism
ICD codes: O88.22, O88.23, O88.211, O88.212, O88.213, O88.219
Drugs: dabigatran
SMILES: CCCCCCOC(=O)\N=C(\N)C1=CC=C(NCC2=NC3=C(C=CC(=C3)C(=O)N(CCC(=O)OCC)C3=NC=CC=C3)N2C)C=C1
Eligibility criteria:

        Inclusion criteria:

          -  Neonates and infants with aged < 12 months at Visit 1

          -  Objective diagnosis of VTE

          -  End of planned treatment course with anticoagulant therapy as per standard of care at
             the investigator site.

          -  Written informed consent provided by the patient's parent(s) (or legal guardian)
             according to local regulations at Visit 1.

        Exclusion criteria:

          -  Weight less than 3 kg at Visit 1

          -  Conditions associated with an increased risk of bleeding

          -  renal dysfunction

          -  hepatic disease

          -  Anemia or thrombocytopenia at screening
Clinical trial NCT02226549 (phase 2, status: completed)
Conditions: hepatitis c virus infection
ICD codes: B00.81, B25.1, B26.81, B58.1, K75.4, A51.45, B17.2
Drugs: ldv/sof, vdv, rbv
SMILES: CC(C)OC(=O)[C@H](C)N[P@](=O)(OC[C@H]1O[C@@H](N2C=CC(=O)NC2=O)[C@](C)(F)[C@@H]1O)OC1=CC=CC=C1, CC[C@@H]1C[C@]1(NC(=O)[C@@H]1C[C@H](CN1C(=O)[C@@H](NC(=O)O[C@@H]1C[C@@H]2C[C@@H]2C1)C(C)(C)C)OC1=C2C=CC(OCCN3CCOCC3)=C(Cl)C2=NC(=C1)C1=CSC(NC(C)C)=N1)C(O)=O, NC(=O)C1=NN(C=N1)[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥ 18 years, with chronic HCV genotype 1 infection

          -  Documentation as treatment-experienced having received pegylated interferon (Peg-IFN)
             + RBV ≥ 4 weeks of duration without an additional agent in the regimen without
             achieving sustained viral response (SVR)

          -  Presence of compensated cirrhosis

          -  Screening laboratory values within defined thresholds

          -  Must use specific contraceptive methods if female of childbearing potential or
             sexually active male

          -  Not pregnant or a nursing female

        Exclusion Criteria:

          -  Co-infection with HIV or hepatitis B virus (HBV)

          -  Current or prior history of clinical hepatic decompensation

          -  Chronic use of systemic immunosuppressive agents

          -  History of clinically significant illness or any other medical disorder that may
             interfere with subject treatment, assessment or compliance with the protocol
Clinical trial NCT02227251 (phase 2, status: active, not recruiting)
Conditions: diffuse large b-cell lymphoma
ICD codes: S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: selinexor
SMILES: FC(F)(F)C1=CC(=CC(=C1)C1=NN(\C=C/C(=O)NNC2=NC=CN=C2)C=N1)C(F)(F)F
Eligibility criteria:

        Inclusion Criteria:

          -  Age ≥18 years

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤ 2

          -  Pathologically confirmed de novo DLBCL

          -  Objective, documented evidence of disease progression on study entry

          -  Have previously received at least 2 but no more than 5 previous systemic regimens for
             the treatment of DLBCL

          -  Have measurable disease

          -  For patients whose most recent anti-DLBCL therapy induced a PR or CR, at least 60 days
             must have elapsed since the end of that therapy. For all other patients, at least 14
             weeks must have elapsed since their most recent systemic anti-DLBCL therapy

        Exclusion Criteria:

          -  DLBCL with mucosa-associated lymphoid tissue (MALT) lymphoma, composite lymphoma
             (HL+NHL) or DLBCL transformed from diseases other than indolent NHL

          -  Must not be eligible for high-dose therapy with autologous stem cell transplantation
             rescue

          -  Primary mediastinal (thymic) large B-cell lymphoma (PMBL)

          -  Known central nervous system (CNS) lymphoma

          -  Active Hepatitis B or C infection

          -  Known human immunodeficiency virus (HIV) infection

          -  Unable to swallow tablets, patients with malabsorption syndrome, or any other GI
             disease or GI function that could interfere with absorption of study treatment
Clinical trial NCT02232880 (phase 2, status: terminated)
Conditions: hypertension
ICD codes: I15.0, I97.3, K76.6, P29.2, G93.2, H40.053, I10
Drugs: abatacept, placebo
SMILES: [H][C@@]12CCCN1C(=O)[C@H](CC1=CC=CC=C1)N1C(=O)[C@](C)(NC(=O)[C@H]3CN(C)[C@]4([H])CC5=CNC6=CC=CC(=C56)[C@@]4([H])C3)O[C@@]21O, CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC2=C(C=CC=C2)C#N)C1=O
Reason stopped: 
    failure to recruit
  
Eligibility criteria:

        Inclusion Criteria:

          -  Men and women 18 to 65 years of age with hypertension, treated with three or more
             anti-hypertensive drugs, one being a diuretic, and

          -  having a systolic blood pressure >150 mmHg in the clinic and daytime average >150 mmHg
             on ambulatory blood pressure monitoring

        Exclusion Criteria:

          -  Medical history of secondary cause of hypertension, severe obesity (BMI >35), severe
             psychiatric disorders, cancer in the last 5 years other than nonmelanoma skin cell
             cancers, herpes zoster or cytomegalovirus that resolved less than 2 months before

          -  Inability to return for abatacept treatment and follow-up for 24 weeks.

          -  Inability to understand or complete study-related assessments.

          -  Current abuse of drugs or alcohol.

          -  Receipt of any live vaccines within 3 months of the anticipated first dose of study
             medication.

          -  Evidence of active or latent bacterial or viral infections at the time of potential
             enrollment, including human immunodeficiency virus (HIV)

          -  Risk for tuberculosis

          -  Abnormal laboratory values including positive hepatitis B surface antigen, hemoglobin
             < 8.5 g/dL, white blood cell count < 3000/mm3, platelets < 100,000/mm3, creatinine >
             2.5 times the upper limit of normal (ULN), alanine aminotransferase or aspartate
             aminotransferase > 2 times the ULN.